NEW YORK (GenomeWeb News) – Applied Proteomics and The ALS Therapy Development Institute (ALS TDI) are collaborating to validate protein biomarkers for tracking the progression of, and developing therapies for, amyotrophic lateral sclerosis, also called Lou Gehrig's disease.

"The absence of viable diagnostic and therapeutic tools for managing and treating ALS is tragic," John Blume, CSO at Applied Proteomics, said in a statement.